Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-25T08:06:15.601Z Has data issue: false hasContentIssue false
  • English
  • Français

A comprehensive study of oxidative stress in patients with somatic symptom disorder

Published online by Cambridge University Press:  18 December 2018

Esra Kabadayi Sahin ,
Ali Caykoylu ,
Almila Senat  and
Ozcan Erel
Esra Kabadayi Sahin*
Affiliation:
Department of Psychiatry, Abant Izzet Baysal University, Izzet Baysal Mental Health Research and Training Hospital, Bolu, Turkey
Ali Caykoylu
Affiliation:
Department of Psychiatry, Ankara Yildirim Beyazit University Medical School, Ankara, Turkey
Almila Senat
Affiliation:
Department of Biochemistry, Ankara Yildirim Beyazit University Medical School, Ankara, Turkey
Ozcan Erel
Affiliation:
Department of Biochemistry, Ankara Yildirim Beyazit University Medical School, Ankara, Turkey
*
Author for correspondence: Esra Kabadayi Sahin, Abant Izzet Baysal University, Izzet Baysal Mental Health Research and Training Hospital, Alpagut Street, Agaccilar Village, Bolu, Turkey. Tel: +00 90 374 275 25 25; Fax: +00 90 374 275 24 23; E-mail: ekabadayi06@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

To investigate oxidative stress parameters [total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), paraoxonase (PON), arylesterase (ARE) and thiol-disulphide homeostasis] in patients who were diagnosed as having somatic symptom disorder in accordance with Diagnostic and Statistical Manual of Mental Disorders-5.

Methods

The study included 41 medication-free patients with somatic symptom disorder and 47 age, sex, and sociodemographic-matched healthy individuals. The patients were administered the Patient Health Questionnaire-15, Somatic Symptom Amplification Scale, Beck Depression Inventory, and Beck Anxiety Inventory. TOS, TAS, OSI, PON, ARE thiol, disulphide levels, and routine biochemical parameters were compared between the two groups.

Results

TOS, OSI, disulphide levels, disulphide/native thiol, and disulphide/total thiol ratios were found significantly higher in the patient group compared with the control group (p < 0.001). There was no significant difference in PON, ARE, and TAS parameters between the two groups (p > 0.05).

Conclusion

This study showed that the level of oxidants increased and oxidative balance was impaired in somatic symptom disorder. Oxidative stress may play a role in the aetiopathogenesis of this disorder. This is the first study to report an association between oxidative stress and somatic symptom disorder.

Keywords

oxidative stressPONSomatic symptom disorderthiol-disulphide homeostasis
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 31 , Issue 2 , April 2019 , pp. 100 - 105
Copyright
© Scandinavian College of Neuropsychopharmacology 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, VA: American Psychiatric Association.Google Scholar
2. Rief, W and Martin, A (2014) How to use the new DSM-5 somatic symptom disorder diagnosis in research and practice: a critical evaluation and a proposal for modifications. Annu Rev Clin Psychol 10, 339–367.Google Scholar
3. Sadock, B, Sadock, V and Ruiz, P (2015) Kaplan & Sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry, 11th edn. Philadelphia, PA: Wolters Kluwer.Google Scholar
4. Poulsen, HE, Specht, E, Broedbaek, K, Henriksen, T, Ellervik, C, Mandrup-Poulsen, T, Tonnesen, M, Nielsen, PE, Andersen, HU and Weimann, A (2012) RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med 52, 1353–1361.Google Scholar
5. Wang, X and Michaelis, E (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2, 12.Google Scholar
6. Ferreira, ME, de Vasconcelos, AS, da Costa Vilhena, T, da Silva, TL, da Silva Barbosa, A, Gomes, AR, Dolabela, MF and Percário, S (2015) Oxidative stress in Alzheimer’s disease: should we keep trying antioxidant therapies? Cell Mol Neurobiol 35, 595–614.Google Scholar
7. Salim, S (2014) Oxidative stress and psychological disorders. Curr Neuropharmacol 12, 140–147.Google Scholar
8. Smaga, I, Niedzielska, E, Gawlik, M, Moniczewski, A, Krzek, J, Przegaliński, E, Pera, J and Filip, M (2015) Pharmacological reports oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacol Rep 67, 569–580.Google Scholar
9. Rief, W, Pilger, F, Ihle, D, Bosmans, E, Egyed, B and Maes, M (2001) Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res 105, 165–174.Google Scholar
10. Rief, W, Pilger, F, Ihle, D, Verkerk, R, Scharpe, S and Maes, M (2004) Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology 49, 24–29.Google Scholar
11. Rief, W and Auer, C (2000) Cortisol and somatization. Biol Psychol. 53, 13–23.Google Scholar
12. Maes, M (2009) Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 22, 75–83.Google Scholar
13. Wolfe, F, Clauw, DJ, Fitzcharles, MA, Goldenberg, DL, Katz, RS, Mease, P, Russell, AS, Russell, IJ, Winfield, JB and Yunus, MB (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62, 600–610.Google Scholar
14. Spitzer, R, deGruy Ill, MD, Hahn, SR, Brody, MD and Johnson, JG (1994) Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA 272, 1749–1756.Google Scholar
15. Kroenke, K, Spitzer, RL and Williams, JB (2002) The PHQ-15: validity of a new measure for evaluating somatic symptom severity. Psychosom Med 64, 258–266.Google Scholar
16. Barsky, AJ, Wyshak, G and Klerman, GL (1990) The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatry Res 24, 323–334.Google Scholar
17. Gulec, H, Sayar, K and Gulec, MY (2007) The reliability and validity of the Turkish form of the somatosensory amplification scale. Dusunen Adam 20, 16–24.Google Scholar
18. Beck, A (1961) An inventory for measuring depression. Arch Gen Psychiatry 4, 561–571.Google Scholar
19. Hisli, N (1998) A study on the validity of the Beck depression inventory. Turk Psychol J 6, 118–123.Google Scholar
20. Beck, A, Epstein, N, Brown, G and Steer, RA (1998) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Phychol 56, 893–897.Google Scholar
21. Ulusoy, M, Sahin, N and Erkmen, H (1998) Turkish version of the Beck anxiety inventory: psychometric properties. J Cogn Psychother 12, 163–172.Google Scholar
22. Erel, O (2004) A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37, 112–119.Google Scholar
23. Erel, O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38, 1103–1111.Google Scholar
24. Haagen, L and Brock, A (1992) A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenylacetate. Clin Chem Clim Biochem 30, 391–396.Google Scholar
25. Erel, O and Neselioglu, S (2014) A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 47, 326–332.Google Scholar
26. Rief, W, Hiller, W and Margraf, J (1998) Cognitive aspects in hypochondriasis and the somatization syndrome. J Abnorm Psychol 107, 587–595.Google Scholar
27. Gaab, J, Rohleder, N, Heitz, V, Schad, T, Engert, V, Schürmeyer, TH and Ehlert, U (2003) Enhanced glucocorticoid sensitivity in patients with chronic fatigue syndrome. Acta Neuropsychiatr 15, 184–191.Google Scholar
28. Hsuchou, H, Kastin, A, Mishra, P and Pan, W (2012) C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem 30, 1109–1119.Google Scholar
29. Maes, M, Twisk, F, Kubera, M and Ringel, K (2012) Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin. J Affect Disord 136, 933–939.Google Scholar
30. Maes, M (2011) An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry 35, 784–794.Google Scholar
31. Maes, M, Ringel, K, Kubera, M, Berk, M and Rybakowski, J (2012) Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 136, 386–392.Google Scholar
32. Codd, EE, Shank, RP, Schupsky, JJ and Raffa, RB (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274, 1263–1270.Google Scholar
33. Hochstrasser, T, Ullrich, C, Sperner-Unterweger, B and Humpel, C (2011) Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience. 184, 128–138.Google Scholar
34. Davies, SJ, Hood, SD, Argyropoulos, SV, Morris, K, Bell, C, Witchel, HJ, Jackson, PR, Nutt, DJ and Potokar, JP (2006) Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J Clin Psychopharmacol 26, 414–418.Google Scholar
35. Stone, TW and Darlington, LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1, 609–620.Google Scholar
36. Huengsberg, M, Winer, J and Round, R (1998) Elevated serum kynurenine level is associated with peripheral neuropathy in HIV. Neuroscience of HIV Infection. J Neurovirol. 4, 353.Google Scholar
37. Koyama, T, McHaffie, J, Laurienti, PJ and Coghill, RC (2005) The subjective experience of pain: where expectations become reality. PNAS. 102, 12950–12955.Google Scholar
38. Anderson, G, Berk, M and Maes, M (2014) Biological phenotypes underpin the physio-somatic symptoms of somatization, depression and chronic fatigue syndrome. Acta Psychiat Scand 129, 83–97.Google Scholar
39. Zhang, W, Li, P, Geng, Q, Duan, Y, Guo, M and Cao, Y (2014) Simultaneous determination of glutathione, cysteine, homocysteine, and cysteinylglycine in biological fluids by ion-pairing highperformance liquid chromatography coupled with precolumn derivatization. J Agric Food Chem 62, 5845–5852.Google Scholar
40. Bass, C and Murphy, M (1995) Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways. J Psychosom Res 39, 403–427.Google Scholar
41. Topcuoglu, C, Bakirhan, A, Yilmaz, F, Neselioglu, S, Erel, O and Sahiner, SY (2017) Thiol/disulfide homeostasis in untreated schizophrenia patients. Psychiatry Res 251, 212–216.Google Scholar
42. Kotan, VO, Yilmaz, FM, Neselioglu, S, Erel, O, Okay, IT, Kiral, S, Bakirhan, A and Goka, E (2017) Thiol/disulphide homeostasis in men with heroin addiction. Dusunen Adam 30, 95–100.Google Scholar
43. Avcil, S, Uysal, P, Avcil, M, Alisik, M and Bicer, C (2017) Dynamic thiol/disulfide homeostasis in children with attention deficit hyperactivity disorder and its relation with disease subtypes. Compr Psychiatry. 73, 53–60.Google Scholar
44. Gumusyayla, S, Vural, G, Bektas, H, Deniz, O, Neselioglu, S and Erel, O (2016) A novel oxidative stress marker in patients with Alzheimer’s disease: dynamic thiol–disulphide homeostasis. Acta Neuropsychiatr 28, 315–320.Google Scholar